Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Overkilling Withdrawn Drugs: FDA Gives Thorough Reassessment For Do-Not-Compound List

This article was originally published in RPM Report

Executive Summary

In its preparations for the first meeting of the rechartered Pharmacy Compounding Advisory Committee, FDA devoted considerable effort to defending the inclusion of two drugs on a list of products withdrawn for reasons of safety and efficacy (and therefore illegal to compound). FDA is understandably concerned about making an airtight case for future enforcement – but it sure seems like a lot of trouble for what should be the easiest task the agency faces in implementing the compounding law.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS079831

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel